Medication info

Pregabalin Capsule 150 mg

Prescription medicationHard capsuleExpired
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
KMS Pharma Co., Ltd.
Appearance
A hard capsule with a white body and a white powder inside.
Packaging
Domestic - 30 capsules/bottle, Domestic - 60 capsules/bottle
Approval status
Expired

MFDS item code 201908674 · Approved 2019.12.27

This product's status changed to Expired on 2024.12.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
Who uses it
Adults · Children
Adult dosage
This medication is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with renal impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalinᵃ / Dosage regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single doseᵇ TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
KMS Pharma Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures with secondary generalized symptoms
  • partial seizures without secondary generalized symptoms
  • fibromyalgia.
View approved original text

This medicine is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in epilepsy patients, applicable whether secondary generalized symptoms are present or not. Additionally, it is effective in alleviating symptoms of fibromyalgia. It aids in managing various neurological disorders and pain, improving the patient's quality of life.

Dosage and Administration

Adult dosage

This medication is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with renal impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalinᵃ / Dosage regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single doseᵇ TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal ideation or behavior, so any changes in mood or unusual behavior during treatment should be reported to a doctor immediately. Do not use if you are allergic to any components in this medication or if you have certain genetic issues such as lactose intolerance. Diabetic patients should be cautious as weight gain during treatment may require adjustment of blood sugar control medications. If symptoms of angioedema occur, such as swelling of the face or around the mouth, discontinue use immediately and consult a healthcare professional. Elderly patients may experience dizziness, drowsiness, or confusion when taking this medication, so care should be taken especially when starting treatment. If vision becomes blurry or changes in eyesight occur, symptoms may improve upon discontinuation of the medication, so monitoring for abnormal symptoms is advised. Abrupt discontinuation or long-term use may result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety; consult with a healthcare professional for dosage adjustments. There is a risk of drug abuse, so individuals with a history of mental health issues or substance abuse should consult prior to use. Patients with impaired kidney function may require dose adjustment. Patients with severe heart disease need to take caution when using this medication and should follow healthcare provider instructions. Co-administration with opioid analgesics may increase the risk of central nervous system depression, so caution is warranted. This medication may cause serious side effects like respiratory depression, so patients with respiratory or kidney disorders should discuss this with their healthcare provider. During early pregnancy, there is a risk of fetal malformation, so women who are pregnant or planning to become pregnant must consult with a doctor before use and should employ effective contraceptive methods. Breastfeeding women should discuss with healthcare providers about either stopping breastfeeding or discontinuing the medication, as this drug can be passed into breast milk and affect the infant. This medication may cause dizziness and drowsiness. Caution is advised when driving or operating machinery, and it is best to avoid hazardous activities until symptoms have completely resolved. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and immediate medical attention is required. Keep this medication out of reach of children and do not transfer it to other containers.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 196 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in eyesight
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • sadness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual paraphilia
  • anxiety
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • flatness
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • reduced reflexes
  • abnormal movements
  • psychomotor agitation
  • position-induced dizziness
  • hypersensitivity
  • burning sensation
  • tremor at rest
  • syncope
  • stupor
  • hypokinesia
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • double vision
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • homonymous bradycardia
  • homonymous tachycardia
  • homonymous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • diaphoresis
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • myotonic contractions
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary dysfunction
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • sensation abnormalities
  • fatigue
  • tightness in the chest
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • altered mental status
  • agitation
  • restlessness
  • worsening of convulsions
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin conditions
  • increased BUN
  • blood in stools
  • fatigue
  • weakness
  • gait abnormalities
  • decreased libido
  • sleep disorders
  • insomnia
  • ataxia
  • speech disorders
  • sensory abnormalities
  • memory impairment
  • attention deficit

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to protect it from air and moisture, ideally at room temperature between 15 to 30 degrees Celsius. This will help maintain the effectiveness of the drug over time.

Appearance and packaging

Appearance

A hard capsule with a white body and a white powder inside.

Package unit

Domestic - 30 capsules/bottle, Domestic - 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.